Gilead Sciences’ Stock Dips as CVS Excludes HIV Drug, but Oncology Acquisition Signals Growth
Gilead Sciences’ stock price declined 1% after CVS excluded its new HIV medication Yeztugo from its formulary, but the company has since made a bold move to expand its oncology pipeline through a $350 million acquisition.
2 minutes to read